Library / Laws / 118th Congress / Senate Bills / S. 1120
S. 1120
To improve the actions available to eligible product developers in the event of delays in receiving covered product for purposes of generic drug or biosimilar biological product development.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in Senate | 2023-03-30 | 4.8K | ⠃⠗⠋ |